Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 per ...

The American Pharmacists Association (APhA) has selected seven recipients of its 2025 Immunization Champion Awards, ...

This can be found among the Granolas, a group of 11 European multinationals, selected by US bank Goldman Sachs, which is made ...

Publicis Groupe has acquired an influencer agency based in Brazil, expanding its presence in the Latin American market. The move aims to leverage the agency’s extensive network of over 500,000 ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...

The U.S. is in a severe flu season, and antiviral medications such as Tamiflu can help if you get sick—but it's not recommended for everyone. Here's what you need to know about the medication.

With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.